Real-world switching and switch-back patterns among patients transitioning from adalimumab to biosimilars in the United States (February 2023 to August 2025).

Karen Gilbert Farrar¹, Nina B Masters¹, Duy Do¹, Nicholas Stucky¹, Brianna M Goodwin Cartwright¹

¹Truveta Inc, Bellevue, WA.

Abstract

BACKGROUND: Adalimumab is a widely used biologic for autoimmune diseases. Biosimilars to adalimumab became available in 2023 and were expected to improve affordability and access, yet real-world evidence on switching after biosimilar initiation remains limited. OBJECTIVE: To assess adoption of adalimumab biosimilars and characterize the frequency and timing of switch-backs to originator adalimuma…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.